Chimeric antigen receptor T-cell (CAR-T) therapy is a form of immunotherapy where patient T cells are genetically engineered to express receptors specific to cancer cells. These engineered T cells are then expanded and reinfused into the patient, where they seek out and destroy cancer cells. CAR-T therapy has shown remarkable success in treating certain blood cancers, particularly B-cell lymphomas and acute lymphoblastic leukemia. The success of CAR-T therapy depends on identifying suitable target antigens that are abundantly expressed on cancer cells but not on healthy cells. For MM, the most prominent targets are: (i) Bcell maturation antigen (BCMA), a protein highly expressed on MM cells, which is critical for their survival. It is the most widely studied and targeted antigen in CAR-T therapy for MM; (ii) while BCMA is the primary target, other antigens such as SLAMF7, CD19, CD138, and GPRC5D are also being explored for CAR-T therapy, particularly in patients who relapse after BCMA-targeted therapy. Approved and investigational CAR-T therapies include: